

8 June 2021

The Manager  
ASX Announcements  
Australian Securities Exchange  
Level 4  
20 Bridge Street  
Sydney NSW 2000

Dear Sir / Madam

**ASX Appendix 3Y**

The Company refers to the ASX release dated 8 June 2021 confirming the vesting of various restricted stock units for the Company's Chief Executive Officer, Dr Mike Perry, in connection with a time-based vesting milestone (i.e. the fourth anniversary of Dr Perry commencing as Chief Executive Officer).

Pursuant to the above, please find attached an ASX Appendix 3Y recording a change in Dr Perry's interests in the Company.

**Please note that the disposal of shares by Dr Perry by way of on market sales (as reflected in the attached ASX Appendix 3Y) are sales executed solely for the purposes of satisfying Dr Perry's income tax liability payable to the U.S. Internal Revenue Service and various U.S. State tax authorities (i.e. all sales are solely to cover income tax liability). Please also note that the additional disposal of shares by Dr Perry by way of transfers (as reflected in the attached ASX Appendix 3Y) are transfers to Dr Perry's former wife in accordance with a marital separation agreement between the parties.**

Authorized by



**Michael Holder**  
Chief Financial Officer

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	AVITA Medical, Inc ("Avita US")
ARBN	641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Perry
Date of last notice	29 March 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
Date of change	1 June 2021, 2 June 2021 and 4 June 2021 (United States)

Appendix 3Y  
Change of Director's Interest Notice

No. of securities held prior to change	<p>634,602 CHESS Depositary Interests ("CDIs") in Avita US quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in Avita US ("Shares")).</p> <p>76,848 Shares quoted on the NASDAQ Stock Market LLC (corrected from 76,846 Shares that was previously disclosed on 29 March 2021).</p> <p>Dr Perry also held the following convertible securities in AVITA Medical Pty Limited ACN 058 466 523 ("<b>Avita Australia</b>"), being a wholly owned subsidiary of Avita US, prior to the change:</p> <ul style="list-style-type: none"> <li>• 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in Avita US)</li> <li>• 14,252,009 unquoted restricted stock units ("<b>RSUs</b>") in Avita Australia (consolidation equivalent = 142,520 unquoted RSUs in Avita US).</li> </ul> <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued Shares in Avita US (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in Avita US's pre-quotation disclosure released to the market on 24 June 2020.</p>
Class	As above
Number acquired	47,506 Shares in Avita US (which do not presently have CDIs issued over them and therefore are not quoted on ASX) acquired on 1 June 2021 (United States).

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	<p>4,750,700 unquoted RSUs in Avita Australia (consolidation equivalent = 47,506 RSUs in Avita US) which were converted into 47,506 Shares that were issued on 1 June 2021 (United States).</p> <p>23,000 Shares disposed of on 2 June 2021 (United States).</p> <p>50,677 Shares disposed of on 4 June 2021 (United States).</p>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Acquisition of 47,506 Shares on 1 June 2021 (United States) – nil consideration (issued as a result of the vesting of the relevant tranche of Dr Perry's unquoted RSUs in Avita Australia).</p> <p>Disposal of 23,000 Shares on 2 June 2021 (United States) – US\$17.338 per share of common stock (being the average price per Share sold).</p> <p>Disposal of 50,677 Shares on 4 June 2021 (United States) – no consideration as transferred to Dr Perry's former wife as part of a marital separation agreement. The estimated value of the 50,677 Shares based on the average trading price of Avita US's Shares on the date of transfer (being US\$17.57 per Share) would be US\$890,394.89.</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held after change</b></p>	<p>634,602 CDIs in Avita US quoted on ASX (representing beneficial ownership of 126,920 Shares).</p> <p>50,677 Shares quoted on the NASDAQ Stock Market LLC.</p> <p>Dr Perry also holds the following convertible securities in Avita Australia, being a wholly owned subsidiary of Avita US:</p> <ul style="list-style-type: none"> <li>• 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in Avita US)</li> <li>• 9,501,400 unquoted RSUs in Avita Australia (consolidation equivalent = 95,014 unquoted RSUs in Avita US).</li> </ul> <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued Shares (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in Avita US's pre-quotations disclosure released to the market on 24 June 2020.</p>
<p><b>Nature of change</b>  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Acquisition of 47,506 Shares on 1 June 2021 (United States) – conversion of unquoted RSUs in Avita Australia</p> <p>Disposal of 23,000 Shares on 2 June 2021 (United States) - on market sale</p> <p>Disposal of 50,677 Shares on 4 June 2021 (United States) due to transfer of Shares to Dr Perry's former wife in accordance with a marital separation agreement</p>

+ See chapter 19 for defined terms.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	Not applicable
<b>Name of registered holder (if issued securities)</b>	Not applicable
<b>Date of change</b>	Not applicable
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Not applicable
<b>Interest acquired</b>	Not applicable
<b>Interest disposed</b>	Not applicable
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Not applicable
<b>Interest after change</b>	Not applicable

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

<sup>+</sup> See chapter 19 for defined terms.